Skip to main content

Clinical Research from Clinical Investigation Services

Call Today to Qualify

Open Hours

Monday – Friday 8 am to 5pm

Have you been diagnosed with Acute Coronary Syndrome (ACS)?

Trial Information:

The LIBREXIA 3003 study by Janssen will study if an experimental drug called milvexian is safe and useful in reducing risk of developing blood clots, stroke, or another heart attach among subjects with a recent heart attack or angina episode, compared to placebo (tablet with no active drug) in addition to standard medication.

Standard medications often prescribed for subjects with a recent heart attack or angina episode may include antiplatelet agents (such as aspirin and other medications that interfere with platelet clumping and thus formation of blood clots), but do not usually include anticoagulants, or blood thinners, that prevent blood clotting through a different mechanism. Milvexian is a type of anticoagulant that may be safer to use than standard anticoagulants for subjects after heart attack or angina episodes.

Dr. Geeta Reddy is the leading physician (called the "principal investigator") for this trial at our affiliate clinic in Libertyville, IL. We are currently accepting new patients for this study.

For more information on this clinical trial, please call us at 847-691-3856 and ask to speak to our recruiter Maria.

Study Protocol: 70033093ACS3003

General Contact Form
Select the best time(s) to contact you.

Dr. Eva Agaiby

President, Director of Clinical Trials & Regulatory Affairs

View Profile

Allen Banoub, MBA

Director of Marketing & Business Development

View Profile